Hologic
HOLX
$76.01
+0.48%
Hologic, Inc. is a specialized healthcare company focused on women's health, developing and supplying diagnostic products, medical imaging systems, and surgical products for early detection and treatment. The company is a market leader in breast health diagnostics and cervical cancer screening, with a distinct competitive identity built on its integrated portfolio across diagnostics, breast imaging, GYN surgical, and skeletal health. The current investor narrative is dominated by a transformative event, as recent news headlines indicate the company is going private in an $18 billion acquisition by Blackstone and TPG, which represents a significant premium and cash payout for shareholders, shifting the debate from public market fundamentals to the terms and future growth trajectory under private equity ownership.…
HOLX
Hologic
$76.01
Related headlines
Investment Opinion: Should I buy HOLX Today?
Rating & Thesis: The recommendation is Hold. The investment thesis is entirely event-driven: public market investors should hold for the acquisition close and cash payout, as the stock price already reflects the deal premium and offers limited standalone upside.
Supporting Evidence: The stock trades at a 52-week high ($76.01 vs. $76.07 high), leaving minimal room for error. Its forward P/E of 15.66x is reasonable but only relevant if the deal closes. Revenue growth is anemic at 2.54% YoY, and analyst sentiment has turned neutral with multiple downgrades. The company's strong cash generation (TTM FCF ~$1.0B) and profitability recovery are positive, but these are now secondary to the merger arbitrage.
Risks & Conditions: The two biggest risks are deal breakage and extended timeline for closure. This Hold rating would upgrade to a tactical Buy only if the stock meaningfully dips below the implied acquisition price on unfounded deal fears, offering a clearer arbitrage spread. It would downgrade to Sell if the acquisition is terminated, as fundamentals do not support the current premium valuation. The stock is fairly valued only relative to the acquisition price; on a standalone basis, it is overvalued given its growth trajectory.
Sign up to view all
HOLX 12-Month Price Forecast
The 12-month outlook is almost entirely binary on the acquisition's success, with a high (75%) probability of a successful close leading to a defined cash payout. The base and bear cases are lower probability but carry significant downside, particularly the bear case which could see a ~32% drop to the 52-week low. The AI stance is Neutral with High confidence because the risk/reward is asymmetric: most upside is capped at the deal price, while downside is substantial if the deal fails. The stance would upgrade to Bullish only if a higher bid materializes; it would downgrade to Bearish immediately upon any credible threat to the deal's completion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hologic's 12-month outlook, with a consensus price target around $98.81 and implied upside of +30.0% versus the current price.
Average Target
$98.81
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$61 - $99
Analyst target range
Analyst coverage for Hologic appears limited in the provided data, with only 7 analysts cited for EPS estimates, and the institutional ratings show a recent pattern of downgrades to Hold or Neutral from firms like JP Morgan, Raymond James, and Mizuho in late 2025. The consensus sentiment has clearly shifted to neutral, with the most recent actions in 2026 from Argus Research (downgrade to Hold) and Evercore ISI (downgrade to In Line) reinforcing a cautious stance. The wide target range implied by the estimated EPS (low of $5.58 to high of $5.87) and revenue estimates (low of $4.80B to high of $4.98B) signals moderate uncertainty, though the recent acquisition announcement fundamentally alters the analyst coverage framework, as the going-private transaction supersedes traditional public market price targets and renders prior upside/downside calculations moot.
Bulls vs Bears: HOLX Investment Factors
The investment thesis for Hologic is overwhelmingly dominated by the pending $18 billion acquisition, which has shifted the debate from public market fundamentals to deal completion risk and final shareholder payout. The bull case is strong and clear, anchored by the acquisition premium, solid profitability recovery, and robust cash flow. The bear case focuses on the company's stagnant organic growth and the fact that the stock is trading at its peak, leaving minimal public market upside. The single most important tension is the certainty and timing of the acquisition closing versus the risk of the deal falling through, which would likely cause the stock to re-price based on its modest growth fundamentals and premium trailing valuation.
Bullish
- Acquisition Premium & Cash Payout: The $18 billion going-private acquisition by Blackstone and TPG represents a significant premium and a definitive cash exit for shareholders. This event has driven the stock to its 52-week high of $76.07, providing a clear near-term catalyst for value realization that supersedes public market fundamentals.
- Strong Profitability & Margin Recovery: The company has demonstrated a sharp rebound in profitability, with Q1 2026 net income of $179.1 million recovering from a net loss of -$17.4 million in Q2 2025. This is supported by a solid gross margin of 55.96% and an operating margin of 17.42%, indicating effective cost management and operational stability.
- Robust Balance Sheet & Cash Flow: Hologic generates substantial free cash flow, with TTM FCF of approximately $1.0 billion and operating cash flow of $229.9 million in the latest quarter. The balance sheet is healthy with a current ratio of 3.75 and a manageable debt-to-equity ratio of 0.52, providing financial flexibility.
- Attractive Forward Valuation: The stock's forward P/E of 15.66x is significantly lower than its trailing P/E of 26.99x, indicating the market expects a substantial earnings rebound. This forward multiple suggests the stock is not excessively valued based on near-term earnings expectations, especially in the context of an acquisition.
Bearish
- Stagnant Revenue Growth: Top-line growth is modest at best, with Q1 2026 revenue of $1.0478 billion representing only 2.54% YoY growth. The multi-quarter trend shows volatility, including a dip to $1.0053 billion in Q2 2025, indicating a business in stabilization rather than acceleration mode.
- Analyst Downgrades & Neutral Sentiment: Multiple firms, including JP Morgan, Raymond James, Mizuho, Argus Research, and Evercore ISI, have recently downgraded HOLX to Hold or Neutral ratings. This consensus shift to caution reflects a lack of conviction in public market upside beyond the acquisition price.
- Limited Public Market Upside: The stock is trading at $76.01, just $0.06 below its 52-week high of $76.07, suggesting most of the acquisition premium is already priced in. With a 1-month gain of only +0.36% and significant underperformance vs. the S&P 500 (-7.00% RS), momentum for further appreciation is weak.
- Premium Trailing Valuation: The trailing P/E of 26.99x is above recent historical averages (e.g., 20.24x in Q4 2025, 18.71x in Q3 2025), indicating the stock trades at a premium to its own recent history. This premium is solely attributable to the acquisition and leaves no margin for operational disappointment.
HOLX Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +24.89%, and is trading at the very top of its 52-week range, with a current price of $76.01 just $0.06 below the 52-week high of $76.07. This positioning near all-time highs suggests strong momentum but also raises questions about potential overextension and limited immediate upside. Recent short-term momentum has been positive but modest, with a 1-month gain of +0.36% and a 3-month gain of +1.47%, indicating a deceleration from the powerful longer-term trend as the stock consolidates near its peak; this is further evidenced by the stock's significant underperformance relative to the S&P 500, with a relative strength of -7.00% over one month. Key technical support is at the 52-week low of $51.90, while immediate resistance is the 52-week high of $76.07; a confirmed breakout above $76.07 could signal a new leg higher, though the stock's low beta of 0.703 indicates it is approximately 30% less volatile than the broader market, which historically suggests more muted price swings and may temper breakout momentum.
Beta
0.70
0.70x market volatility
Max Drawdown
-15.4%
Largest decline past year
52-Week Range
$52-$76
Price range past year
Annual Return
+24.9%
Cumulative gain past year
| Period | HOLX Return | S&P 500 |
|---|---|---|
| 1m | +0.4% | +8.5% |
| 3m | +1.5% | +2.8% |
| 6m | +11.2% | +4.6% |
| 1y | +24.9% | +32.3% |
| ytd | +1.9% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HOLX Fundamental Analysis
Revenue growth has been modest but positive, with the most recent quarterly revenue of $1.0478 billion representing a year-over-year growth of 2.54%; however, examining the multi-quarter trend reveals volatility, with revenue dipping to $1.0053 billion in Q2 2025 before recovering, indicating a stabilization rather than robust acceleration. The company is solidly profitable, posting net income of $179.1 million in Q1 2026, with a strong gross margin of 55.96% and an operating margin of 17.42%; profitability has rebounded sharply from a net loss of -$17.4 million in Q2 2025, demonstrating effective recovery from a temporary trough. The balance sheet and cash flow position are robust, with a healthy current ratio of 3.75, a manageable debt-to-equity ratio of 0.52, and substantial free cash flow generation, as evidenced by TTM free cash flow of approximately $1.0 billion and an operating cash flow of $229.9 million in the latest quarter, providing ample internal funding for operations and strategic initiatives.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$999599999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HOLX Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 26.99x, while the forward PE is significantly lower at 15.66x, indicating the market expects a substantial rebound in earnings growth over the next twelve months. Compared to sector averages, the stock's trailing PE of 26.99x and Price-to-Sales (PS) ratio of 3.72x are not directly comparable without a provided industry benchmark, but the forward PE discount suggests the market may be pricing in a normalization post-acquisition or sector headwinds. Historically, the stock's current trailing PE of 26.99x sits above its recent quarterly average seen in the historical data (e.g., 20.24x in Q4 2025, 18.71x in Q3 2025), indicating the stock is trading at a premium to its own recent history, which likely reflects the acquisition premium being priced into the shares rather than operational improvements.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -199x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not from debt or cash burn, as the balance sheet is strong (D/E 0.52, Current Ratio 3.75), but from revenue stagnation. With YoY growth of just 2.54% and quarterly volatility, the business lacks a clear growth engine independent of the acquisition. Profitability, while recovered, remains susceptible to margin pressure, as evidenced by the gross margin decline from 60.90% in Q4 2025 to 55.96% in Q1 2026. The valuation relies on the acquisition; absent the deal, the trailing P/E of 26.99x appears rich for single-digit growth.
Market & Competitive Risks: The paramount market risk is deal breakage. Should the acquisition fail to close, the stock would face significant valuation compression from its current premium trailing P/E (26.99x) down toward its recent historical average near 20x, implying a ~26% downside. Competitive and regulatory risks in women's health diagnostics persist, but the stock's low beta of 0.703 indicates it is less sensitive to broad market swings, though it has recently underperformed the S&P 500 significantly (-7.00% over one month).
Worst-Case Scenario: The worst-case scenario is the acquisition deal collapsing due to regulatory rejection, financing issues, or a material adverse change in Hologic's business. This would trigger a rapid re-rating of the stock based on its fundamental growth profile. A realistic downside target would be a return to its 52-week low of $51.90, representing a potential loss of approximately -32% from the current price of $76.01. Analyst downgrades to Sell would likely follow, accelerating the decline.
FAQ
The key risks are: 1) Deal Completion Risk: The acquisition could fail due to regulatory or financing issues, causing a sharp decline. 2) Fundamental Stagnation Risk: Standalone revenue growth is weak at 2.54% YoY. 3) Valuation Risk: The trailing P/E of 26.99x is high for its growth profile, posing downside if the deal falls through. 4) Market Risk: Recent underperformance vs. the S&P 500 (-7.00% over one month) suggests weak momentum independent of the deal. Deal breakage is the most severe risk by far.
The forecast is scenario-based due to the acquisition. The Bull Case (75% probability) sees the stock reaching the deal price, target range $76.07-$78.00, upon successful closure. The Base Case (20%) anticipates minor deal delays, with the stock range-bound between $70.00-$76.07. The Bear Case (5%) forecasts a collapse to $51.90-$65.00 if the deal fails. The most likely outcome is the Bull Case, with the key assumption being that the $18 billion acquisition by Blackstone and TPG closes as planned.
HOLX's valuation is bifurcated. On a standalone basis, it is overvalued, trading at a trailing P/E of 26.99x, which is a premium to its recent historical average (~20x) and difficult to justify given its modest 2.54% revenue growth. However, relative to the pending acquisition, the stock is fairly valued, as the price reflects the anticipated takeover premium. The forward P/E of 15.66x is reasonable but only meaningful if the deal completes. The market is valuing HOLX as an acquisition target, not as a going concern.
HOLX is a good buy only for investors comfortable with merger arbitrage, seeking to capture the final spread between the current price (~$76.01) and the eventual acquisition cash payout. For traditional investors looking for growth or value, it is not a good buy, as standalone upside is limited with revenue growth at just 2.54% and the stock at its 52-week high. The biggest risk is deal breakage, which could cause a ~32% drop to the 52-week low of $51.90. It is a suitable, lower-volatility (beta 0.70) holding for those with high conviction in the deal closing.
HOLX is strictly a short- to medium-term investment tied to the acquisition event horizon. The investment thesis evaporates once the deal closes and shareholders are cashed out. Its low beta of 0.70 and defined exit make it unsuitable for long-term growth portfolios. The suggested minimum holding period is until deal completion, expected within 6-12 months. Long-term investors should look elsewhere, as HOLX will cease to be a public company.
